Sunovion Pharmaceuticals Inc.

Pureform Global, Inc.

Surendra Singh

Roger P Bakale

Harold Scott Wilkinson

Stefan G Koenig

Charles P Vandenbossche

Hang Zhao

H Scott Wilkinson

Zhengxu Han

Mark A Varney

Thomas Wessel

Judy Caron

Michael Joseph Sizensky

Cai Gu Huang

Karim Lalji

Philip James Bonasia

Xiping Su

Sharon M Laughlin

Paul Herrinton

Susan S D'Souza

Marc Bencivenga

Paul Jass

Matthew Forster

Todd Zahn

Disclosed herein are embodiments of a method for making cannabidiol. Also disclosed herein are embodiments of a composition comprising cannabidiol and one or more GRAS components. The method and composition embodiments described herein address the drawbacks associated with conventional methods for making and/or isolating cannabidiol.

Synthetic cannabidiol compositions and methods of making the same

This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.

Preparation of chiral amides and amines

Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.

Formulations, salts and polymorphs of transnorsertraline and uses thereof

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine

Growing community of inventors

Shrewsbury, MA, United States of America

Surendra Singh